Favoring the Ombudsman’s withdrawal of complaints filed against Pharmally Pharmaceuticals, the Sandiganbayan has decided to allow the refiling of the cases, pointing out that double jeopardy has not yet applied on the issue.
In an eight-page resolution, the anti-graft court gave credence to the the petion of the Office of the Ombudsman to withdraw graft cases against Pharmally as it rejected claims of political persecution or due process violations.
The Sandiganbayan’s 1st Division noted that Ombudsman Jesus Crispin ‘Boying’ Remulla has the authority to review cases and overturn or repeal actions taken by his predecessor, former ombudsman Samuel Martires.
On record, barely a week from his appointment as Ombudsman, Remulla had ordered the recall of all criminal cases against Pharmally filed in courts where the accused have not yet been arraigned.
The cases against the firm stem from alleged irregularities in the procurement of medical supplies, Covid-19 test kits and personal protective equipment (PPE) worth billions of pesos by the Department of Health (DoH) and the Department of Budget and Management’s Procurement Service (DBM-PS) during the pandemic period under the Duterte administration.
Three complaints originally filed with the Manila Regional Trial Court were later transferred to a Malolos regional court for violation of the Anti-Graft and Corrupt Practices Act. The Malolos court, citing lack of jurisdiction, referred the cases to the Sandiganbayan, which affirmed it was the proper court to hear them.
The first case involved the June 2020 purchase of 41,400 units of BGI Real-Time Fluorescent RT-PCR kits worth ₱2.8 billion. DBM-PS defendants were named than as undersecretary and executive director Lloyd Christopher Lao, procurement group director Warren Rex Liong and procurement officers Augusto Ylagan, Webster Laureñana and Paul Jasper de Guzman.
In the second case, the issue in question was ₱600-million purchase of 8,000 PCR kits while the third case involved the April 2020 procurement of 2,000 A Star Fortitude RT-PCR kits worth ₱688 million.
Additional DBM-PS officials implicated included Christine Marie Suntay and Jasonmer Uayan.
Other defendants listed across all three cases were Pharmally president Twinkle Dargani, treasurer and secretary Mohit Dargani, directors Linconn Ong and Justine Garado, board member Huang Tzu Yen, employee Krizzle Grace Mago and financial manager Lin Weixiong.
Some of the defendants opposed the Ombudsman’s withdrawal of the cases with Ong arguing that the prosecution’s motion lacked legal merit and was driven by “malice and politics.”
Ong likewise warned that a reinvestigation would cause unwarranted delays.
Corollary to this, Liong opined that the Remulla’s motion to withdraw should be denied because probable cause had already been established. Lin Weixiong also criticized the withdrawal as based solely on the Ombudsman’s preference.
For his part, Mohit Dargani enthused that he did not oppose the withdrawal but he has asked the anti-graft court to dismiss the cases with prejudice even as he argued that refiling would amount to political persecution and violate his right to due process and the speedy resolution of cases.
However, the Sandiganbayan cited that the fear of delays “is merely speculative at this point since no reinvestigation has yet been conducted and no result has been rendered therefrom.”
It asserted that as a general rule, courts do not interfere with the Ombudsman’s determination of probable cause unless there is clear evidence of grave abuse of discretion.
“We do not interfere with the Ombudsman’s exercise of its investigative and prosecutorial powers, and respect the initiative and independence inherent in its office,” the court stated as it’s conclusive argument.